Menu
Skills in this repository
SkillsMP has collected 858 skills from dromlakhani/MD2SKILL. Open a skill to review its source and details.
dromlakhani/MD2SKILLShowing 40 of 858 collected skills.
Differentiate the seven enzymatic forms of congenital adrenal hyperplasia (CAH) presenting in the newborn or young infant — StAR (lipoid CAH), CYP11A1 (P450scc), HSD3B2 (3β-HSD), CYP17A1 (17α-hydroxylase/17,20-lyase), CYP21A2 (classic 21-hydroxylase), CYP11B1…
Bedside prescribing reference for Bemdec (bempedoic acid / NEXLETOL) — indication check, dose, statin co-prescribing safety caps, monitoring plan, warnings for hyperuricemia and tendon rupture, and special population guidance. Use when a clinician asks "can I…
Work up a patient with confirmed hypercalcemia using the PTH-dependent vs. PTH-independent algorithm — order the right second-tier tests (PTHrP, 25(OH)D, 1,25(OH)2D, SPEP/UPEP, urinary calcium/creatinine clearance ratio, TSH) to reach a diagnosis. Trigger…
Classify the severity of hypercalcemia at the bedside — mild, moderate, or severe — by combining the corrected/ionized calcium level with the acuity and symptom pattern, and decide whether the patient needs urgent therapy. Trigger when a clinician asks "is…
Work up Malignancy-Associated Hypercalcemia (MAH) — distinguish humoral hypercalcemia of malignancy (HHM, PTHrP-driven), local osteolytic hypercalcemia, 1,25(OH)2D-mediated lymphoma hypercalcemia, ectopic PTH secretion, and multiple myeloma — and pick the…
Screen a hypercalcemic patient for medication- and supplement-induced causes — thiazides, lithium, vitamin D, vitamin A/retinoids, antiestrogens, theophylline, milk-alkali, SGLT2 inhibitors, immune checkpoint inhibitors, denosumab rebound,…
Bedside prescribing reference for Mounjaro (tirzepatide) — indications, dose escalation, missed-dose rule, KwikPen vs prefilled pen differences, contraindications, warnings, storage, and monitoring. Use when a clinician asks how to start tirzepatide, how to…
Match an adult obese patient to the best-fit evidence anchor for Noveltreat (semaglutide 2.4 mg) using the 7 Sun Pharma monograph obesity profiles — medically-supervised weight loss, obese + uncontrolled T2DM, obese + CVD / HFpEF risk, obese + knee…
Bedside prescribing reference for Noveltreat (Sun Pharma semaglutide 0.25/0.5/1/1.7/2.4 mg pre-filled pen) for chronic weight management — adult indication criteria, 5-step dose escalation, missed-dose rule, contraindications, warnings, drug interactions, and…
Storage, handling, and disposal of the Noveltreat pre-filled semaglutide injection pen (0.25 / 0.5 / 1 / 2.4 mg, Sun Pharma) — fridge rules, 28-day out-of-fridge limit, single-use, pen-lock mechanism, light and freeze precautions, biomedical-waste disposal.…
Check whether an adolescent aged 12 to under 18 years qualifies for Wegovy (semaglutide 2.4 mg) using BMI age-sex 95th-percentile cutoff, weight above 60 kg threshold, and secondary-obesity exclusion. Use when a clinician asks "is my teenager eligible for…
Bedside prescribing reference for Wegovy (semaglutide 2.4 mg) — adult and pediatric indications, 16-week dose-escalation schedule, missed-dose rule, 12-week continuation rule, contraindications, warnings, and monitoring. Use when a clinician asks how to start…
Step-by-step meal planning for a patient with obesity — from diet recall to calorie prescription to macronutrient targets. Use when a clinician asks "how do I plan a diet for my obese patient", "what calorie target for weight loss", "how many calories should…
Select oral and injectable glucose-lowering agents for a newly diagnosed patient with type 2 diabetes using a compelling-indication hierarchy (heart failure → ASCVD → DKD → obesity) followed by glucose-pattern matching. Incorporates modern GLP-1 receptor…
Decides whether a thyroid nodule needs FNA biopsy using the ATA 2015 sonographic pattern classification (high/intermediate/low/very low/benign) and nodule size thresholds. Use when a clinician asks "does this thyroid nodule need a biopsy", "should I FNA this…
Classify a thyroid nodule using the EU-TIRADS system from an ultrasound image or US report, and give a risk-stratified FNA recommendation. Use when a clinician shares a thyroid ultrasound image or describes US features of a nodule and asks "what is the…
Step-wise management of constipation caused by defecatory disorder (pelvic floor dysfunction, dyssynergia, outlet obstruction) using the WGO cascade framework. Trigger when a patient strains excessively even with soft stools, uses manual manoeuvres to…
Selects the right pharmacologic treatment for chronic constipation using a resource-stratified cascade approach (Level 1/2/3), with doses and NNTs for each agent. Trigger when a clinician asks which laxative to use, what to prescribe for constipation, how to…
Complete bedside prescribing reference for Movicol (macrogol 3350 + electrolytes) covering dosing for chronic constipation and faecal impaction, special population adjustments, contraindications, warnings, and drug interactions. Trigger when a clinician asks…
Complete bedside prescribing reference for Mirago (mirabegron, beta-3 adrenoceptor agonist) for overactive bladder — covering contraindications, safety screening, drug interactions, dose selection in special populations, titration, and administration. Use…
Decide whether commonly-excluded patients (eating disorders, elderly ≥75, upper GI disease) can actually receive a GLP-1 receptor agonist. Use when a clinician asks "can I give semaglutide to a patient with binge eating disorder / anorexia / bulimia", "is…
Apply the four published expert-consensus clinical scenarios to manage GI adverse events in complex GLP-1 receptor agonist patients — persistent nausea mid-titration, GERD/heartburn after up-titration, elderly with sarcopenia risk, and insulin-treated elderly…
Decide how to modify GLP-1 receptor agonist dose-escalation when GI adverse events appear during titration — extend, hold, step-back, set sub-maximal maintenance, or switch agent — using CTCAE grading of nausea and the "start low, go slow" flexible-titration…
Counsel a patient before starting a GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, oral semaglutide) on how to prevent GI adverse events — nausea, vomiting, diarrhoea, constipation. Use when a clinician asks for…
Select the right rescue medication for GI adverse events caused by a GLP-1 receptor agonist — antiemetics for nausea/vomiting, antidiarrhoeals for diarrhoea, stool softeners for constipation, plus drug-interaction adjustments. Use when a clinician asks "which…
Provide symptom-specific dietary and lifestyle advice for a patient on a GLP-1 receptor agonist who has developed nausea, vomiting, diarrhoea, or constipation. Use when a clinician asks "what to advise for nausea/vomiting/diarrhoea/constipation on…
Reduce the dose of basal insulin or sulfonylurea when starting or escalating a GLP-1 receptor agonist (Mounjaro/tirzepatide or Wegovy/Ozempic/semaglutide) to avoid hypoglycemia. Use when a clinician asks "how much to reduce insulin when starting Ozempic",…
Look up drug-specific nausea and vomiting rates across the full generation of GLP-1-based obesity agents — semaglutide 2.4 mg, semaglutide 7.2 mg, CagriSema, tirzepatide, retatrutide, survodutide, oral semaglutide 25/50 mg, and orforglipron — to counsel…
Counsel patients on oral hormonal contraceptive interaction with tirzepatide (Mounjaro) — requirement for non-oral contraception or added barrier method for 4 weeks after initiation and 4 weeks after each dose escalation. Use when a clinician asks "does…
Assess and monitor pancreatobiliary risk (acute pancreatitis, cholelithiasis, cholecystitis, lipase/amylase elevations) in patients on GLP-1 receptor agonists. Use when a clinician asks about gallstone risk on semaglutide/liraglutide/tirzepatide, "GLP-1 and…
Guide perioperative decisions for patients on GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide) undergoing general anesthesia, deep sedation, or endoscopy — whether to hold, how long, and how to weigh aspiration risk from delayed…
Adjust basal insulin dose (Lantus, Basaglar, Ryzodeg/IDegAsp) based on fasting blood glucose trend. Use when a clinician asks how to titrate basal insulin, whether to increase or decrease Lantus/glargine/degludec/Ryzodeg dose, or how to adjust basal insulin…
Adjust basal insulin dose day-to-day in a hospitalised patient being managed for glucocorticoid-induced hyperglycemia (GCIH) using the Lakhani protocol. Trigger when a clinician asks "how to titrate basal insulin in steroid patient", "adjust glargine for…
Select the correct type and dose of "correctional insulin" to co-administer with a glucocorticoid in a hospitalised patient with glucocorticoid-induced hyperglycemia (GCIH). Trigger when a clinician asks "what insulin to give with steroids", "which insulin…
Classify a hospitalised patient on glucocorticoids as established diabetic (Group 1) or new glucocorticoid-induced hyperglycemia without prior DM (Group 2), then determine whether background basal-bolus insulin is needed and at what starting dose based on…
Determine the supplemental premeal short-acting insulin dose for a hospitalised patient on the GCIH protocol, based on premeal capillary blood glucose. Use two separate scales: standard (experimental/Lakhani protocol) and insulin-resistant (control/Endocrine…
Algorithm for interpreting metanephrine results and handling borderline elevations in suspected Pheochromocytoma. Trigger when a clinician asks "how to interpret metanephrines", "metanephrine units", or "borderline metanephrine result".
Pre-operative preparation protocol for Pheochromocytoma, focusing on alpha-blockade titration and volume expansion. Trigger when a clinician asks "prep for pheo surgery", "alpha blockade vs beta blockade", or "doxazosin titration".
First-line screening logic to identify patients who require biochemical testing for Pheochromocytoma or Paraganglioma. Trigger when a clinician asks "who to screen for pheo", "evaluation of adrenal incidentaloma", or "workup for paroxysmal hypertension."
Decide whether a newly-diagnosed multiple myeloma (NDMM) patient is eligible for high-dose melphalan + autologous stem cell transplantation (ASCT) as part of front-line therapy, using the EHA-ESMO 2021 criteria. Trigger when a clinician asks "is this myeloma…